Eric Batts, MD
Hematology & Oncology · Holland, MINPI 1821126830
Payments from drug & device makers
What this record shows
This record is dominated by food and beverage: $7,878 of the $9,034 with a category attached, or 87.2%. It is spread thinly across 59 manufacturers, the largest accounting for just 13.6% — the pattern of someone who eats at a lot of different presentations.
Across 381 payments — averaging $23.71 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Daiichi Sankyo Inc.$1K
- AstraZeneca$682
- Novartis$592
- Pfizer$422
- Merck$420
- Genentech USA, Inc.$407
- plus $5K from 53 others
Across 79 payments — averaging $20,711 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- AstraZeneca$1M
- Merck$249K
- Seagen Inc.$172K
- Pfizer$112K
- AbbVie$53K
- Daiichi Sankyo Inc.$28K
What the payments were for
- Consulting fees$94010%
- Food & beverage$7,87887%
- Education$2162%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- ILLUCCIX$200
- FOUNDATIONONE$112
- FOUNDATIONONE HEME$112
- FOUNDATIONONE CDX$112
- FOUNDATIONFOCUS$112
- FOUNDATIONONE LIQUID$112
- Truqap$106
How this compares
$9,034 in reported general payments places this provider in the 80th percentile of 282 hematology & oncology providers in Michigan.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| ImbruvicaIbrutinib | 161 | $2,277,040 |
| Abiraterone Acetate | 498 | $1,518,618 |
| RevlimidLenalidomide | 76 | $1,267,900 |
| XtandiEnzalutamide | 145 | $1,211,279 |
| CabometyxCabozantinib S-Malate | 64 | $1,179,979 |
| JakafiRuxolitinib Phosphate | 54 | $912,200 |
| VenclextaVenetoclax | 78 | $743,900 |
| OjjaaraMomelotinib Dihydrochloride | 26 | $697,294 |
| InlytaAxitinib | 38 | $644,269 |
| WeliregBelzutifan | 21 | $616,309 |
| BrukinsaZanubrutinib | 39 | $518,265 |
| CalquenceAcalabrutinib Maleate | 33 | $478,878 |
| BosulifBosutinib | 28 | $440,956 |
| VonjoPacritinib Citrate | 17 | $423,628 |
| VerzenioAbemaciclib | 13 | $201,084 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Pharmacyclics LLC, An Abbvie CompanyImbruvica | $230 | $2,277,040161 claims |
| PfizerInlyta, Bosulif, Ibrance, Nyvepria, Eliquis | $422 | $1,444,595192 claims |
| Bristol Myers SquibbRevlimid | $147 | $1,267,90076 claims |
| Astellas Pharma US IncXtandi | $269 | $1,211,279145 claims |
| Exelixis Inc.Cabometyx | $146 | $1,179,97964 claims |
| Incyte CorporationJakafi | $166 | $912,20054 claims |
| AbbVieVenclexta | $224 | $743,90078 claims |
| GSKOjjaara | $234 | $697,29426 claims |
| MerckWelireg | $420 | $616,30921 claims |
| Beigene USA, Inc.Brukinsa | $98 | $518,26539 claims |
| AstraZenecaCalquence | $682 | $478,87833 claims |
| NovartisKisqali, Tafinlar | $592 | $364,15423 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 80th percentile of 282 hematology & oncology providers in Michigan.
Other hematology & oncology in Holland
- Faisal MusaDearborn$976K
- Mohammed Al HallakDetroit$644K
- Daniel LebovicGrosse Pointe Woods$352K
- Sreenivasa ChandanaGrand Rapids$305K
- Mohammad ChistiTroy$180K
- Gordon SrkalovicLansing$167K
- Jeffrey ZonderDetroit$88K
- Madan AroraFlint$84K
- Hadeel AssadDetroit$80K
- Andrew MuskovitzSouthfield$45K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.